One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Praxis Precision Medicines logo
Praxis Precision Medicines PRAX
$ 267.68 6.11%
report update icon

Quarterly report 2026-Q2
added 08-06-2026

Praxis Precision Medicines Cash Flow 2025-2011 | PRAX

Brief cash flow overview of Praxis Precision Medicines

This overview follows the five latest available annual observations in the 2021–2025 interval.

The latest year produced an operating outflow of -$249.1 million. A return to positive cash generation is important.

Positive operating cash flow appeared only 0 times out of five; a stable cash profile has not formed.

Overall picture

Taken together, Praxis Precision Medicines's cash flow indicators point to increased dependence on reserves or outside financing.

Annual Cash Flow Praxis Precision Medicines

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-249 M -132 M -111 M -185 M -125 M -52.6 M -33.4 M - - - - - - - -

Depreciation & Amortization

140 K 358 K 432 K 419 K 182 K 50 K 37 K - - - - - - - -

Accounts Payables

24.6 M 12.5 M 5.82 M 14.7 M 10.8 M 4.09 M - - - - - - - - -

All numbers in USD currency

Quarterly Cash Flow Praxis Precision Medicines

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

-164 M -86.2 M - - -53 M - - - -20.9 M - - - -32.8 M - -156 M -111 M -54.1 M - -79.7 M -55.7 M -25.7 M - -32.4 M -18.5 M -8.57 M - -23.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

72 K 39 K - - 47 K - - - 112 K - - - 106 K - 314 K 212 K 93 K - 89 K 50 K 23 K - 30 K 20 K 10 K - 27 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Payables

23.4 M 31.2 M 30.8 M 28.8 M 22.9 M 12.5 M 15 M 8.2 M 9.4 M 5.82 M 7.17 M 8.01 M 17 M 14.7 M 10.1 M 11.8 M 13.3 M 10.8 M 7.54 M 7.4 M 5.77 M 4.09 M 4.09 M 4.09 M 4.09 M 2.67 M 2.67 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Praxis Precision Medicines, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
Sierra Oncology Sierra Oncology
SRRA
- -0.05 % $ 1.34 B canadaCanada
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Holding Corp.
TNXP
$ 5.31 2.42 % $ 45.2 M usaUSA
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 4.16 2.97 % $ 339 M usaUSA
Tenax Therapeutics Tenax Therapeutics
TENX
$ 1.65 -4.07 % $ 64.7 M usaUSA
Vaccinex Vaccinex
VCNX
- -61.37 % $ 654 K usaUSA
Trevi Therapeutics Trevi Therapeutics
TRVI
$ 12.51 -0.83 % $ 1.69 B usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
- -19.68 % $ 18.4 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Taysha Gene Therapies Taysha Gene Therapies
TSHA
$ 4.0 0.88 % $ 1.28 B usaUSA
Jounce Therapeutics Jounce Therapeutics
JNCE
- - $ 98.4 M usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
- - $ 69.7 B britainBritain
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 49.0 -0.79 % $ 4.41 B schweizSchweiz
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 10.44 -0.9 % $ 824 M usaUSA
UroGen Pharma Ltd. UroGen Pharma Ltd.
URGN
$ 34.05 -1.29 % $ 1.64 B israelIsrael
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
United Therapeutics Corporation United Therapeutics Corporation
UTHR
$ 593.02 0.94 % $ 26.3 B usaUSA
Vericel Corporation Vericel Corporation
VCEL
$ 42.99 1.08 % $ 2.16 B usaUSA
Veracyte Veracyte
VCYT
$ 48.22 0.61 % $ 3.79 B usaUSA
Champions Oncology Champions Oncology
CSBR
$ 4.82 2.12 % $ 66.7 M usaUSA
Mersana Therapeutics Mersana Therapeutics
MRSN
- - $ 3.56 B usaUSA
Vir Biotechnology Vir Biotechnology
VIR
$ 11.02 4.27 % $ 1.53 B usaUSA
Viking Therapeutics Viking Therapeutics
VKTX
$ 24.23 -0.72 % $ 2.73 B usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc
FRLN
- - $ 384 M britainBritain
Cabaletta Bio Cabaletta Bio
CABA
$ 1.34 -9.18 % $ 135 M usaUSA
CytomX Therapeutics CytomX Therapeutics
CTMX
$ 2.23 -4.09 % $ 308 M usaUSA
Vanda Pharmaceuticals Vanda Pharmaceuticals
VNDA
$ 3.95 -1.62 % $ 233 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Timber Pharmaceuticals Timber Pharmaceuticals
TMBR
- - $ 717 K usaUSA
Verrica Pharmaceuticals Verrica Pharmaceuticals
VRCA
$ 3.4 -3.68 % $ 36.2 M usaUSA
Viridian Therapeutics Viridian Therapeutics
VRDN
$ 23.31 4.2 % $ 2.37 B usaUSA
G1 Therapeutics G1 Therapeutics
GTHX
- - $ 370 M usaUSA
Verastem Verastem
VSTM
$ 9.9 -1.34 % $ 686 M usaUSA
VistaGen Therapeutics VistaGen Therapeutics
VTGN
$ 0.17 -3.9 % $ 6.47 M usaUSA
Voyager Therapeutics Voyager Therapeutics
VYGR
$ 1.76 0.86 % $ 103 M usaUSA
Amryt Pharma plc Amryt Pharma plc
AMYT
- - $ 621 M britainBritain
Kinnate Biopharma Kinnate Biopharma
KNTE
- - $ 123 M usaUSA
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
- - $ 7.29 B usaUSA
NexImmune NexImmune
NEXI
- 70.13 % $ 4.12 M usaUSA
Wave Life Sciences Ltd. Wave Life Sciences Ltd.
WVE
$ 3.23 -0.16 % $ 545 M singaporeSingapore
Theravance Biopharma Theravance Biopharma
TBPH
$ 17.03 0.03 % $ 857 M cayman-islandsCayman-islands
Xenetic Biosciences Xenetic Biosciences
XBIO
$ 1.72 3.78 % $ 2.93 M usaUSA
XBiotech XBiotech
XBIT
$ 1.82 -5.7 % $ 55.5 M usaUSA
Xenon Pharmaceuticals Xenon Pharmaceuticals
XENE
$ 35.76 1.19 % $ 2.83 B canadaCanada
Xeris Pharmaceuticals Xeris Pharmaceuticals
XERS
$ 10.21 0.05 % $ 1.64 B usaUSA
X4 Pharmaceuticals X4 Pharmaceuticals
XFOR
$ 3.26 0.46 % $ 138 M usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
22nd Century Group 22nd Century Group
XXII
$ 0.09 -54.43 % $ 16.6 K usaUSA